Sigourney Bell (Sigourney Bonner)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Tyrosine Kinase

Childhood Cancer

Top Venues

Molecular cancer therapeutics

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher M Bourne, Henry J Henderson, Elshaddai White, Julia Morris, Mamadou A Bah, Rhea Harewood, Stephanie A Pierre, Tanimola Martins, Tumisang Ntereke, Briana White, Sigourney Bell
Black in Cancer: Two Years of Empowering the Next Generation. Cancer discovery 13 (2) (2023)
Larissa S Carnevalli, Molly Ann Taylor, Matthew King, Anna M L Coenen-Stass, Adina M Hughes, Sigourney Bell, Theresa A Proia, Yanjun Wang, Antonio Ramos-Montoya, Neha Wali, Danielle Carroll, Maneesh Singh, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Susan E Critchlow, Teresa Klinowska, Stephen E Fawell, Simon T Barry
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition. Molecular cancer therapeutics 20 (6) (2021)
Henry J Henderson, Sigourney Bell
Black in Cancer: Championing Diversity in Cancer Research and Medicine. Cancer discovery 11 (2) (2021)
Vikki Flemington, Emma J Davies, David Robinson, Linda C Sandin, Oona Delpuech, Pei Zhang, Lyndsey Hanson, Paul Farrington, Sigourney Bell, Katarzyna Falenta, Francis D Gibbons, Nicola Lindsay, Aaron Smith, Joanne Wilson, Karen Roberts, Michael Tonge, Philip Hopcroft, Sophie E Willis, Martine P Roudier, Claire Rooney, Elizabeth A Coker, Patricia Jaaks, Mathew J Garnett, Stephen E Fawell, Clifford D Jones, Richard A Ward, Iain Simpson, Sabina C Cosulich, J Elizabeth Pease, Paul D Smith
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. Molecular cancer therapeutics 20 (2) (2020)